Ascendis Pharma AS (MEX:ASNDN) Tariff Resilience Score: 7/10 (As of Jun. 25, 2026)


MEX:ASNDN Ascendis Pharma AS MEX:ASNDN
37 GF Score
Price MXN3,851.44
! 1 Warning Sign
View Full Analysis

What is Ascendis Pharma AS Tariff Resilience Score?

Ascendis Pharma AS MEX:ASNDN 37 Tariff Resilience Score is 7 as of Jun. 25, 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,379 Biotechnology companies, Ascendis Pharma AS ranks better than 90.43% on this metric.

Ascendis Pharma AS has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Ascendis Pharma AS has Ascendis Pharma's operations are primarily in Europe, with a focus on pharmaceuticals, which often have tariff exemptions. The company has limited exposure to tariffs due to its specialized supply chain and strong pricing power in niche markets.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Ascendis Pharma AS might have Highly Resilient.

Ascendis Pharma AS  (MEX:ASNDN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Ascendis Pharma AS Tariff Resilience Score Related Terms

MEX:ASNDN vs SMMT, BBIO, JAZZ: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Pharma AS Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Tariff Resilience Score falls into.


MEX:ASNDN
37GF Score
Ascendis Pharma AS MEX:ASNDN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Ascendis Pharma AS (MEX:ASNDN) has a Tariff Resilience Score of 7 as of Jun. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Ascendis Pharma AS ranks #132 out of 1379 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Ascendis Pharma AS's Tariff Resilience Score too high?
Ascendis Pharma AS's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Ascendis Pharma AS's value of 7 is 75% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #132 out of 1379 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Tariff Resilience Score compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #132 out of 1379 companies for Tariff Resilience Score. This places Ascendis Pharma AS in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Ascendis Pharma AS's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,379 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current Tariff Resilience Score is 7 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for MEX:ASNDN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,851.44
Price